Lexeo Therapeutics (LXEO) Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics has disclosed Accumulated Expenses across 5 years of filings, most recently posting $8.2 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $8.2 million, down 49.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (down 49.62% YoY), and the FY2025 annual result was $9.3 million, up 125.61% from the prior year.
• Accumulated Expenses came in at $8.2 million for Q1 2026 at Lexeo Therapeutics, down from $9.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.2 million in Q1 2025 to a low of $1.8 million in Q3 2023.
• The 5-year median for Accumulated Expenses is $7.3 million (2022), against an average of $7.8 million.
• Across the five-year window, Accumulated Expenses surged 764.43% in 2024 and slumped 81.0% in 2025, its largest moves.
• Lexeo Therapeutics' Accumulated Expenses stood at $6.4 million in 2022, then surged by 68.85% to $10.8 million in 2023, then tumbled by 62.07% to $4.1 million in 2024, then soared by 125.61% to $9.3 million in 2025, then dropped by 12.05% to $8.2 million in 2026.
• The last three Accumulated Expenses figures came in at $8.2 million (Q1 2026), $9.3 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.